INTRA-CELLULAR THERAPIES, INC. — Department of Health and Human Services SBIR Phase I: PAR-11-133 - PI, Gretchen L. Snyder, PhD Casein Kinase I Inhibitors for Autism Project Sum

Description

PAR-11-133 - PI, Gretchen L. Snyder, PhD Casein Kinase I Inhibitors for Autism Project Summary/Abstract Autism is a neurodevelopmental disorder characterized by abnormal social interaction, deficits in interpersonal communication, and repetitive stereotyped behaviors with a number of individually- occurring associated symptoms, including intellectual impairment, anxiety, seizures, hyperactivity, hyper- or hypo-responsiveness to sensory stimulation, sleep disruption, and gastrointestinal abnormalities. It isnoteworthy that hyperactivity, impulsivity, and inattention-core features of attention deficit hyperactivity disorder (ADHD)-occur as associated symptoms in a high percentage (41-78%) of autistic individuals. As a complex, multi-symptom disorder, a largenumber of gene mutations (heritable and de novo) as well as environmental and epigenetic factors are likely involved in the expression of autism. Currently, there is no cure or satisfactory treatment for autism. New therapeutic agents that would effective